Ascletis PharmaASCLF -4.00%38 Market Cap is $1,498.07 Mil as of Jul. 12, 2026. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, Ascletis Pharma ranks better than 83.77% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ascletis Pharma's share price for the quarter that ended in Dec. 2025 was $1.485. Ascletis Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 986.09 Mil. Therefore, Ascletis Pharma's market cap for the quarter that ended in Dec. 2025 was $1,464.34 Mil.
Ascletis Pharma's quarterly market cap
increased
from Dec. 2024 ($230.86 Mil) to Jun. 2025 ($897.85 Mil) and
increased
from Jun. 2025 ($897.85 Mil) to Dec. 2025 ($1,464.34 Mil).
Ascletis Pharma's annual market cap
increased
from Dec. 2023 ($175.39 Mil) to Dec. 2024 ($230.86 Mil) and
increased
from Dec. 2024 ($230.86 Mil) to Dec. 2025 ($1,464.34 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ascletis Pharma's Enterprise Value for Today is $1,219.22 Mil.
Ascletis Pharma (OTCPK:ASCLF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ascletis Pharma Market Cap Related Terms
Ascletis Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ascletis Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ascletis Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Market Cap of $1,498.07 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ascletis Pharma and its competitors. According to the industry distribution chart, Ascletis Pharma ranks #231 out of 1423 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Ascletis Pharma's Market Cap too high?
Ascletis Pharma's current Market Cap is $1,498.07 Mil. The Biotechnology industry median Market Cap is 121.30. Ascletis Pharma's value of $1,498.07 Mil is 1135% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #231 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #231 out of 1423 companies for Market Cap. This places Ascletis Pharma in the top 16% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.30. Ascletis Pharma's value of $1,498.07 Mil is 1135% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.30, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Market Cap of $1,498.07 Mil is 1135% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 121.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Market Cap is $1,498.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Market Cap is $1,498.07 Mil and 1135% above the Biotechnology industry median of 121.30. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Market Cap is $1,498.07 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Market Cap: $1,498.07 Mil
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
Industry Position: 1135% above the Biotechnology median (#231 of 1423)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
